The University of Southampton
University of Southampton Institutional Repository

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor. Here circulating tumor DNA (ctDNA) was detected in 29% of patients after 6-12 weeks of combination therapy (compared to 70% before any treatment) and associated with 12 month overall survival of 73% versus 99% for patients who were ctDNA-negative and 24 month survival of 50% versus 85%. The secondary objective was to test ctDNA with serum prostate-specific antigen (PSA). In multivariable models, both were independent risk factors on combination treatment with a hazard ratio of death of 20.34 for the poorest prognosis group, but only ctDNA was associated with shorter survival on androgen deprivation before the start of combination therapy. Using ctDNA with serum PSA and clinical characteristics can improve the accuracy of survival prediction and should be evaluated for ctDNA-informed treatment modification. ClinicalTrials.gov: NCT04067713 .

2662-1347
915-927
Jayaram, Anuradha
913c560c-f64c-43c9-94a7-cf389b84b1fd
Rashid, Memuna
7f83a017-1e55-4b0a-a39d-2ea33ef6df60
Reid, Alison H.M.
c6b62c75-046a-43d8-9208-cf6b6ad2f9d1
Orlando, Francesco
52738fd2-b8fd-43b4-bc97-510b3d74e853
Thakali, Suparna
0bc3ef9d-0f9e-48be-bd33-f155e5ea8791
Zakka, Leila
a459ab94-3602-4df7-9777-6a7f88913599
Goncalves, Miriam
0e8a860e-94d8-412c-8ffe-e8f4acb33b4d
O'Dwyer, Jacqueline
4b1ccd0a-c428-4779-83a2-7e579c98c1ee
Alifrangis, Constantine
73bae054-84f4-445f-81b3-2680b5c487bd
Jones, Rob
cd0b6c2a-900e-40a6-8011-2cebf14d632e
Pintus, Elias
ed7a64c4-a304-4b46-a84b-d11b2533bf98
Needleman, Sarah
6dd4c403-8a4d-4e50-98ef-5d8dbcbad0b4
Bianchini, Diletta
3fb6ab4f-ea97-4dd3-9875-acd2d8f8c4ab
Wingate, Anna
5d756e85-f78f-47b7-be10-431e9b8bee78
Ng, Kenrick
05d4d703-8b18-4ac2-8264-a9bd8de82759
Linch, Mark
c677c64a-517b-4055-9041-085a4db008a0
McGovern, Ursula
1b594073-cdb4-463d-af5d-2f9f0706903f
Staffurth, John
51734078-ea1f-4188-8d32-75f786921586
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Brock, Susannah
5a4351f1-52a5-465f-a420-65209be18de2
Birtle, Alison
1031c636-ab1a-4bc5-b053-5f1334c6c087
Vainauskas, Osvaldas
04142024-3460-4d20-98ff-3a0fc707f414
Leone, Gianmarco
cdb327e9-1d17-4004-b768-6008ba8cbf20
Chiwewe, Millenn
cc0dd01a-d8d9-4d6d-96c2-cd8504539b16
Hackshaw, Allan
fabfe335-1aa6-4634-9d4a-0a1f3fac5b32
Lopes, Andre
ea53f5b4-ac6c-4033-8d81-77aff7c0a908
Wetterskog, Daniel
6f3eb6d4-6cbf-4d43-b848-1cc7ff427e1e
Demichelis, Francesca
de7fbbed-389c-4e4c-a9b2-e848fd060f28
Attard, Gerhardt
21aa794b-ef60-483c-baae-cf6464cb2efa
et al.
Jayaram, Anuradha
913c560c-f64c-43c9-94a7-cf389b84b1fd
Rashid, Memuna
7f83a017-1e55-4b0a-a39d-2ea33ef6df60
Reid, Alison H.M.
c6b62c75-046a-43d8-9208-cf6b6ad2f9d1
Orlando, Francesco
52738fd2-b8fd-43b4-bc97-510b3d74e853
Thakali, Suparna
0bc3ef9d-0f9e-48be-bd33-f155e5ea8791
Zakka, Leila
a459ab94-3602-4df7-9777-6a7f88913599
Goncalves, Miriam
0e8a860e-94d8-412c-8ffe-e8f4acb33b4d
O'Dwyer, Jacqueline
4b1ccd0a-c428-4779-83a2-7e579c98c1ee
Alifrangis, Constantine
73bae054-84f4-445f-81b3-2680b5c487bd
Jones, Rob
cd0b6c2a-900e-40a6-8011-2cebf14d632e
Pintus, Elias
ed7a64c4-a304-4b46-a84b-d11b2533bf98
Needleman, Sarah
6dd4c403-8a4d-4e50-98ef-5d8dbcbad0b4
Bianchini, Diletta
3fb6ab4f-ea97-4dd3-9875-acd2d8f8c4ab
Wingate, Anna
5d756e85-f78f-47b7-be10-431e9b8bee78
Ng, Kenrick
05d4d703-8b18-4ac2-8264-a9bd8de82759
Linch, Mark
c677c64a-517b-4055-9041-085a4db008a0
McGovern, Ursula
1b594073-cdb4-463d-af5d-2f9f0706903f
Staffurth, John
51734078-ea1f-4188-8d32-75f786921586
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Brock, Susannah
5a4351f1-52a5-465f-a420-65209be18de2
Birtle, Alison
1031c636-ab1a-4bc5-b053-5f1334c6c087
Vainauskas, Osvaldas
04142024-3460-4d20-98ff-3a0fc707f414
Leone, Gianmarco
cdb327e9-1d17-4004-b768-6008ba8cbf20
Chiwewe, Millenn
cc0dd01a-d8d9-4d6d-96c2-cd8504539b16
Hackshaw, Allan
fabfe335-1aa6-4634-9d4a-0a1f3fac5b32
Lopes, Andre
ea53f5b4-ac6c-4033-8d81-77aff7c0a908
Wetterskog, Daniel
6f3eb6d4-6cbf-4d43-b848-1cc7ff427e1e
Demichelis, Francesca
de7fbbed-389c-4e4c-a9b2-e848fd060f28
Attard, Gerhardt
21aa794b-ef60-483c-baae-cf6464cb2efa

Jayaram, Anuradha, Rashid, Memuna and Reid, Alison H.M. , et al. (2026) Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study. Nature Cancer, 7 (6), 915-927. (doi:10.1038/s43018-026-01172-9).

Record type: Article

Abstract

The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor. Here circulating tumor DNA (ctDNA) was detected in 29% of patients after 6-12 weeks of combination therapy (compared to 70% before any treatment) and associated with 12 month overall survival of 73% versus 99% for patients who were ctDNA-negative and 24 month survival of 50% versus 85%. The secondary objective was to test ctDNA with serum prostate-specific antigen (PSA). In multivariable models, both were independent risk factors on combination treatment with a hazard ratio of death of 20.34 for the poorest prognosis group, but only ctDNA was associated with shorter survival on androgen deprivation before the start of combination therapy. Using ctDNA with serum PSA and clinical characteristics can improve the accuracy of survival prediction and should be evaluated for ctDNA-informed treatment modification. ClinicalTrials.gov: NCT04067713 .

This record has no associated files available for download.

More information

Accepted/In Press date: 13 April 2026
e-pub ahead of print date: 15 May 2026
Published date: June 2026

Identifiers

Local EPrints ID: 515337
URI: https://eprints.soton.ac.uk/id/eprint/515337
ISSN: 2662-1347
PURE UUID: d1c1dd54-1f0f-4d62-b242-32d777d8ef16
ORCID for Simon J. Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 13 Oct 2026 16:31
Last modified: 14 Oct 2026 01:41

Export record

Altmetrics

Contributors

Author: Anuradha Jayaram
Author: Memuna Rashid
Author: Alison H.M. Reid
Author: Francesco Orlando
Author: Suparna Thakali
Author: Leila Zakka
Author: Miriam Goncalves
Author: Jacqueline O'Dwyer
Author: Constantine Alifrangis
Author: Rob Jones
Author: Elias Pintus
Author: Sarah Needleman
Author: Diletta Bianchini
Author: Anna Wingate
Author: Kenrick Ng
Author: Mark Linch
Author: Ursula McGovern
Author: John Staffurth
Author: Simon J. Crabb ORCID iD
Author: Susannah Brock
Author: Alison Birtle
Author: Osvaldas Vainauskas
Author: Gianmarco Leone
Author: Millenn Chiwewe
Author: Allan Hackshaw
Author: Andre Lopes
Author: Daniel Wetterskog
Author: Francesca Demichelis
Author: Gerhardt Attard
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×